Better decisions
Better medicines
PhaseV brings clinical, statistical, and AI expertise into one connected platform, so teams can reduce uncertainty, test the decisions that matter, and carry approved choices through to delivery.
About us
Every clinical program is shaped by decisions made long before the first patient is enrolled, and each one affects the study that follows.
We bring scientific, clinical, and operational expertise into a single view, so sponsors can spot risk sooner and act with confidence.
Our goal is to help development teams run trials that are better designed, better understood, and better prepared to deliver for patients.
PhaseV at a glance
Trusted across clinical development
50+
Sponsors and CROs
10
Of the top 20 pharmaceutical companies
100+
Clinical trials supported
10M+
Patient-level records
50+
Disease models
10+
Scientific papers
Leadership
Raviv Pryluk, PhD
CEO, Co-Founder
Elad Berkman, MSc
CTO, Co-Founder
Dan Goldstaub, PhD
Scientific Co-Founder
Raviv Pryluk, PhD
Raviv Pryluk, PhD
Elad Berkman, MSc
Elad Berkman, MSc
Dan Goldstaub, PhD
Dan Goldstaub, PhD
Klaus Beck, MD, PhD, PhD
Former SVP & CMO, Organon
Sofia Villar, PhD
Professor, University of Cambridge
William F. Doyle
Executive Chairman, Novocure
Avi Kulkarni, PhD
CEO, InoRx
Howard Trachtman, MD
Former Professor of Pediatrics, NYU Langone Health
Murray Urowitz, MD
Professor of Medicine, University of Toronto
Investors
Backed by leading investors
PhaseV is supported by investors in technology, life sciences, and healthcare.
Build with us
Work at the intersection of science, technology, and medicine
PhaseV brings together clinicians, statisticians, data scientists, engineers, product builders, and customer teams across Boston and Tel Aviv. We work on difficult questions with rigor, candor, curiosity, and a bias toward practical impact.
Multidisciplinary by default
Practical impact
Global collaboration
Scientific rigor